Moleculin gets Japanese patent allowance for Annamycin reconstitution methods

Moleculin Biotech, Inc.

Japan Patent Office issued notice of allowance for Patent App. 2021-577862 covering liposomal Annamycin preparation methods.
Patent expected to issue in coming months; complements existing US and European Annamycin patents.
Annamycin (naxtarubicin) is in Phase 3 for relapsed/refractory AML with FDA Fast Track and Orphan Drug designations.
CEO Klemp states the allowance strengthens international IP for non-cardiotoxic anthracycline therapy.
Additional Annamycin-related patent applications are pending in major jurisdictions worldwide.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.